Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.60 |
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9036399 | 1.00 | ACE (0.64) | ACECYP19A1TACR1MMP3MMP8 | |
| SCHEMBL9038284 | 1.00 | ACE (0.64) | ACECYP19A1TACR1MMP3MMP8 | |
| SCHEMBL10636863 | 0.92 | CYP19A1 (0.58) | ACECYP19A1TACR1 | |
| SCHEMBL10847229 | 0.86 | CYP19A1 (0.52) | ACECYP19A1TACR1 | |
| SCHEMBL10847994 | 0.86 | CYP19A1 (0.52) | ACECYP19A1TACR1 | |
| SCHEMBL9052688 | 0.85 | CYP19A1 (0.54) | ACECYP19A1TACR1 | |
| SCHEMBL10807258 | 0.84 | CYP19A1 (0.52) | ACECYP19A1TACR1 | |
| SCHEMBL10640576 | 0.84 | CYP19A1 (0.50) | ACECYP19A1TACR1 | |
| SCHEMBL799730 | 0.83 | ACE (0.60) | ACECYP19A1MMP3MMP8 | |
| SCHEMBL29929342 | 0.83 | ACE (0.60) | ACECYP19A1MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157834-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-6720330-B2 | INCREASING SECRETION OF GROWTH HORMONE, GASTRIN, OR GLUCAGON IN A MAMMAL; INHIBITING THE BINDING OF SOMATOSTATIN TO AN SST2 RECEPTOR | PFIZER INC. | 2004-04-13 | — | — | US | disclosed |
| US-20020091125-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | HAY BRUCE A (US) | 2002-07-11 | — | — | US | disclosed |
| EP-0145304-B1 | TETRAHYDRO-BETA-CARBOLINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Tanabe Seiyaku Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4628057-A | Tetrahydro-β-carboline derivatives and treatment of liver diseases | TANABE SEIYAKU CO., LTD. (JP) | 1986-12-09 | — | — | US | disclosed |
| EP-0145304-A1 | Tetrahydro-beta-carboline derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157834-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | SSTR2, GHSR, SSTR1 | ACE 1263/4885CYP19A1 488/4885TACR1 77/4885 |
| US-20020091125-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | SSTR2, GHSR, SSTR1 | ACE 1365/4885CYP19A1 509/4885TACR1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.